Therapeutic innovations in COVID-19: anti-spike biologics with pan-variant activity (ECCMID 2022) - Mar 22, 2022 - Pres time: Apr 26, 2022; 08:30 AM - 10:30 AM; Location: Hall P; "Organised by: Novartis To inform ECCMID delegates and the wider scientific and medical community of the mode of action and clinical data on ensovibep, a Designed Ankyrin Repeat Protein (DARPin) anti-spike biologic therapeutic, for the treatment of COVID-19."
Infectious Disease • Novel Coronavirus Disease
|
|
Isabelle SCHALK; Tobias WELTE
|